Skip to main navigation Skip to search Skip to main content

A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY® Study)

Project: Research project

Project Details

StatusActive
Effective start/end date8/25/25 → 8/24/27

Funding

  • Boehringer Ingelheim International GmbH ( Award # ): $23,360.00